Overview

ABI-009 (Nab-rapamycin) in Combination With FOLFOX and Bevacizumab as First-line Therapy in Patients With Advanced or Metastatic Colorectal Cancer

Status:
Recruiting

Trial end date:
2023-12-01

Target enrollment:

Participant gender:

Summary

A phase 1/2 multi-center investigation of ABI-009 (nab-rapamycin) in combination with mFOLFOX6 and Bevacizumab as first-line therapy in patients with advanced or metastatic colorectal cancer

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Aadi, LLC

Treatments:

Bevacizumab
Everolimus
Sirolimus